Explore the Potential with AI-Driven Innovation
This extensive focused library is tailor-made using the latest virtual screening and parameter assessment technology, operated by the Receptor.AI drug discovery platform. This technique is more effective than traditional methods, offering compounds with improved activity, selectivity, and safety.
We carefully select specific compounds from a vast collection of over 60 billion molecules in virtual chemical space. Our partner Reaxense helps in synthesizing and delivering these compounds.
Contained in the library are leading modulators, each labelled with 38 ADME-Tox and 32 physicochemical and drug-likeness qualities. In addition, each compound is illustrated with its optimal docking poses, affinity scores, and activity scores, giving a complete picture.
We employ our advanced, specialised process to create targeted libraries for enzymes.
Fig. 1. The sreening workflow of Receptor.AI
It includes comprehensive molecular simulations of the catalytic and allosteric binding pockets and the ensemble virtual screening accounting for their conformational mobility. In the case of designing modulators, the structural changes induced by reaction intermediates are taken into account to leverage activity and selectivity.
Key features that set our library apart include:
partner
Reaxense
upacc
Q96SB4
UPID:
SRPK1_HUMAN
Alternative names:
SFRS protein kinase 1; Serine/arginine-rich protein-specific kinase 1
Alternative UPACC:
Q96SB4; B4DS61; Q12890; Q5R364; Q5R365; Q8IY12
Background:
SRSF protein kinase 1, also known as Serine/arginine-rich protein-specific kinase 1, plays a pivotal role in post-transcriptional gene regulation by phosphorylating splicing factors. This kinase is crucial for the regulation of splicing, influencing the distribution of splicing factors in cells and the reorganization of nuclear speckles. Its activity extends beyond splicing, impacting chromatin organization, cell cycle progression, and even viral replication processes.
Therapeutic significance:
Understanding the role of SRSF protein kinase 1 could open doors to potential therapeutic strategies.